{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-087924","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.287601+00:00","generated_at":"2026-06-24T02:18:32.672151+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaccitech reports Q2 net income of $15.7M on $17.1M in Vaxzevria royalties","bullets":["Net income $15.7M ($0.41 diluted EPS) vs $2.6M ($0.068) in Q1 2022.","Revenue $17.1M from milestone/royalty payments from AstraZeneca for Vaxzevria sales.","Cash $192.3M at June 30 vs $214.1M at Dec 31, 2021; $15.0M used in operations.","R&D expenses $9.7M (down from $10.7M); G&A excluding FX gain was $8.8M.","Clinical highlights: VTP-300 HBV data, EMA advice for MERS vaccine, HPV trial enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-087924","json":"https://secwatch.observer/filing/0001104659-22-087924.json","markdown":"https://secwatch.observer/filing/0001104659-22-087924.md","text":"https://secwatch.observer/filing/0001104659-22-087924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922087924/0001104659-22-087924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465922087924/tm2222823d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:18:32.672151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}